Industry News
We've paid the price, now let us work: Amrad boss
Gently suggesting that analysts and investors should back off and let Amrad focus on its product development, managing director Sandra Webb presented Amrad as a case study on maturing public biotechnology companies at the AusBiotech 2002 conference. [ + ]
Second BIF grant gives Protagonist an edge
For drug design start-up Protagonist, tucking a second BIF grant in as many years under its belt should help smooth future discussions with commercial partners. [ + ]
Heavy R&D spend sees Antisense book $6.3m loss
Biopharmaceutical research and development company Antisense Therapeutics reported on Wednesday a net loss of $6.3 million for the 12 months to June 30, 2002, driven largely by heavy early-stage expenditure on R&D, the company said. [ + ]
CSIRO aims to strengthen its biotech focus
CSIRO has launched a biotechnology strategy in an attempt to strengthen its focus in the field. [ + ]
IDT posts profit record number eight
Australian drug discovery company International Drug Technologies has announced a record 14 per cent jump in full year net profit to $4.2 million. [ + ]
Top scientist backs both adult and embryonic cell research
Leading scientist Catherine Verfaillie has told a briefing in Melbourne it was "unfortunate" that her work was held up as evidence that embryonic stem cell research was unnecessary. [ + ]
Circular protein research heads latest BIF grant parade
The Federal government is gambling $250,000 that Australian researchers can produce a commercial payoff from world-leading work on an unusual family of circular proteins. [ + ]
Get it together on stem cells, warns Macfarlane
Industry Minister Ian Macfarlane last night warned scientists that the real threat to the future of stem cell research in Australia was because of researchers' conflicting goals. [ + ]
CM Capital fund gets set to invest
A new Australian $54 million venture fund is ready to invest in promising young biotechs even though it is far short of its intended goal of raising $100 to $150 million. [ + ]
Online wine fermentation monitoring technology
An automatic system to continuously monitor and control wine fermentations being developed by University of South Australia and University of Adelaide researchers will enable winemakers to produce better quality wine and maintain Australia's competitiveness in international wine markets.
[ + ]Progen teams with CSIRO in manufacturing deal
Australia's largest contract drug manufacturer, Progen Industries, and CSIRO are marrying their bio-manufacturing skills. [ + ]
Put your pedal to the metal: BIO chief
It's time for biobusiness to accelerate without looking back, the chair of the US Biotechnology Industry Organisation (BIO), David Robinson, told the AusBiotech conference in Melbourne this week. [ + ]
Drug company forms manufacturing alliance with CSIRO
Biotechnology company Progen Industries Ltd and the CSIRO have signed a Memorandum of Understanding (MOU) for the research, development and manufacture of new drugs.
[ + ]Chemeq tops Deloitte WA index
Western Australian biotech Chemeq has topped a Deloitte Touche Tohmatsu index highlighting the market performance of WA listed companies over the last two years. [ + ]
Cerylid appoints expat high-flyer to advisory board
Melbourne-based Cerylid Biosciences has appointed another internationally experienced scientist to its advisory board. [ + ]